Clinical studies of pemetrexed and gemcitabine combinations

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Pemetrexed (ALIMTA™) is a novel multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. This agent is broadly active in a wide variety of solid tumors, including breast cancer, bladder cancer, mesothelioma, non-small-cell lung cancer, pancreatic cancer and ovarian cancer. Pemetrexed has also shown clinically relevant activity in combination with gemcitabine. This combination has been, and continues to be evaluated for the treatment of a number of malignancies, including non-small cell lung and ovarian cancer. A recently published randomized trial of different sequences has identified the sequence of pemetrexed on day 1 followed by gemcitabine on day 1 and gemcitabine on day 8, every 21 days as the most efficacious and least toxic sequence.

Original languageEnglish (US)
JournalAnnals of Oncology
Volume17
Issue numberSUPPL. 5
DOIs
StatePublished - May 1 2006

Fingerprint

gemcitabine
Pemetrexed
Urinary Bladder Neoplasms
Non-Small Cell Lung Carcinoma
Ovarian Neoplasms
Hydroxymethyl and Formyl Transferases
Folic Acid Antagonists
Poisons
Mesothelioma
Pancreatic Neoplasms
Neoplasms
Breast Neoplasms
Clinical Studies

Keywords

  • Dihydrofolate reductase
  • Glycinamide ribonucleotide formyltransferase
  • Multitargeted antifolate
  • Thymidylate synthase

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Clinical studies of pemetrexed and gemcitabine combinations. / Adjei, Alex.

In: Annals of Oncology, Vol. 17, No. SUPPL. 5, 01.05.2006.

Research output: Contribution to journalArticle

@article{d50dc257cdcf4b138715d5277ad012bf,
title = "Clinical studies of pemetrexed and gemcitabine combinations",
abstract = "Pemetrexed (ALIMTA™) is a novel multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. This agent is broadly active in a wide variety of solid tumors, including breast cancer, bladder cancer, mesothelioma, non-small-cell lung cancer, pancreatic cancer and ovarian cancer. Pemetrexed has also shown clinically relevant activity in combination with gemcitabine. This combination has been, and continues to be evaluated for the treatment of a number of malignancies, including non-small cell lung and ovarian cancer. A recently published randomized trial of different sequences has identified the sequence of pemetrexed on day 1 followed by gemcitabine on day 1 and gemcitabine on day 8, every 21 days as the most efficacious and least toxic sequence.",
keywords = "Dihydrofolate reductase, Glycinamide ribonucleotide formyltransferase, Multitargeted antifolate, Thymidylate synthase",
author = "Alex Adjei",
year = "2006",
month = "5",
day = "1",
doi = "10.1093/annonc/mdj946",
language = "English (US)",
volume = "17",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "SUPPL. 5",

}

TY - JOUR

T1 - Clinical studies of pemetrexed and gemcitabine combinations

AU - Adjei, Alex

PY - 2006/5/1

Y1 - 2006/5/1

N2 - Pemetrexed (ALIMTA™) is a novel multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. This agent is broadly active in a wide variety of solid tumors, including breast cancer, bladder cancer, mesothelioma, non-small-cell lung cancer, pancreatic cancer and ovarian cancer. Pemetrexed has also shown clinically relevant activity in combination with gemcitabine. This combination has been, and continues to be evaluated for the treatment of a number of malignancies, including non-small cell lung and ovarian cancer. A recently published randomized trial of different sequences has identified the sequence of pemetrexed on day 1 followed by gemcitabine on day 1 and gemcitabine on day 8, every 21 days as the most efficacious and least toxic sequence.

AB - Pemetrexed (ALIMTA™) is a novel multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. This agent is broadly active in a wide variety of solid tumors, including breast cancer, bladder cancer, mesothelioma, non-small-cell lung cancer, pancreatic cancer and ovarian cancer. Pemetrexed has also shown clinically relevant activity in combination with gemcitabine. This combination has been, and continues to be evaluated for the treatment of a number of malignancies, including non-small cell lung and ovarian cancer. A recently published randomized trial of different sequences has identified the sequence of pemetrexed on day 1 followed by gemcitabine on day 1 and gemcitabine on day 8, every 21 days as the most efficacious and least toxic sequence.

KW - Dihydrofolate reductase

KW - Glycinamide ribonucleotide formyltransferase

KW - Multitargeted antifolate

KW - Thymidylate synthase

UR - http://www.scopus.com/inward/record.url?scp=33745609549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745609549&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdj946

DO - 10.1093/annonc/mdj946

M3 - Article

VL - 17

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL. 5

ER -